Assessing the Impact of Plasma Cell-Free DNA Methylation Monitoring on Predicting Pathological Outcomes in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer: Insights from a Prospective Phase II Study - Top-Institutions - MDSpire

Assessing the Impact of Plasma Cell-Free DNA Methylation Monitoring on Predicting Pathological Outcomes in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer: Insights from a Prospective Phase II Study

  • By

  • Bing Liu

  • Ye Tao

  • Minglei Zhuo

  • Li-Di Xu

  • Xueyan Cheng

  • Wei Tao

  • Zhangdong Xie

  • Chao Lv

  • Yuzhao Wang

  • Shaolei Li

  • Shanyuan Zhang

  • Miao Huang

  • Yaqi Wang

  • Xiang Li

  • Yuge Zhu

  • Xinrui Cui

  • Xuantong Zhou

  • Bateer Han

  • Enli Zhang

  • Yu S. Huang

  • Weizhi Chen

  • Jia Wang

  • Shi Yan

  • Nan Wu

  • November 5, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Thoracic Oncology
    • Molecular Diagnostics
    • Liquid Biopsy Research

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Thoracic Oncology
    • Cancer Epigenetics
    • Liquid Biopsy

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Thoracic Oncology
    • Translational Cancer Research
    • Liquid Biopsy

  • #4

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Cancer Genomics
    • Liquid Biopsy
    • Thoracic Oncology

Original Source(s)

Assessing the Impact of Plasma Cell-Free DNA Methylation Monitoring on Predicting Pathological Outcomes in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer: Insights from a Prospective Phase II Study

  • by Bing Liu, Ye Tao, Minglei Zhuo, Li-Di Xu, Xueyan Cheng, Wei Tao, Zhangdong Xie, Chao Lv, Yuzhao Wang, Shaolei Li, Shanyuan Zhang, Miao Huang, Yaqi Wang, Xiang Li, Yuge Zhu, Xinrui Cui, Xuantong Zhou, Bateer Han, Enli Zhang, Yu S. Huang, Weizhi Chen, Jia Wang, Shi Yan, Nan Wu

  • November 5, 2025

Related Content

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship